RCTs: Once daily oral relugolix combination therapy vs. placebo in patients with endometriosis-associated pain.

Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) – The Lancet

Commentaries:

Relugolix combination therapy for endometriosis pain – The Lancet (free registration required)

Relugolix demonstrates positive phase 3 data as combination therapy for endometriosis pain – Contemporary OB/GYN

Commentary on Twitter

Treatment options for #endometriosis-associated pain are suboptimal.

Two new studies indicate once-daily relugolix combination therapy significantly improved pain and was well tolerated. 1/2 https://t.co/LBFgTMZSO2

— The Lancet (@TheLancet) June 21, 2022